Laboratory of Biopharmaceuticals
The laboratory conducts structure-functional research of biologically active peptides, peptidomimetics and other organic molecules. Besides fundamental research purposes (drug discovery) the Laboratory is engaged in applied research of prospective drug candidates for the purposes of creation of new medical products (drug development).
The Laboratory’s research has resulted in several peptide pharmaceuticals acting on a wide range of targets: the immune system, as well as the central and peripheral nervous systems. These drugs are aimed at treatment of autoimmune and neurodegenerative diseases, immunodeficiencies, inflammatory diseases, and alcoholism.
As a result of prior work of the laboratory’s lead researchers, two original peptide drugs targeting the immune system have received regulatory approval for the Russian market:
– "Thymodepressin" – an immunosuppressive agent which is approved for use in adults and children for the treatment of autoimmune diseases such as psoriasis, rheumatoid arthritis and others.
– "Stemokin" – an immunostimulant and a hematopoiesis booster, is approved for the treatment of secondary immunodeficiencies.
The laboratory also studies neuropeptides acting on the central nervous system. It has conducted research work on the following neuropeptides currently in Phase II clinical trials:
– "Sedatin" drug (IBCh-05) is an antagonist of the mu-opioid receptor which has anxiolytic and anti-anxiety properties. Currently in Phase II clinical trials in Russia.
– “Opilong” drug (IBCh-07) is a selective agonist of the mu-opioid receptors which inhibits the alcohol dependence. Currently in Phase II clinical trials in Russia.
In collaboration with other laboratories of the IBCh, our Laboratory has conducted research on "Sevanol", a new biologically active compounds isolated from natural raw materials, which has analgesic and anti-inflammatory properties. We have also collaborated on a new drug for the prevention of Alzheimer's disease.
The Laboratory has developed and patented in a number of leading countries an original concept of improving the stability of low molecular weight peptide compounds to enzymatic hydrolysis when administered orally. Also on the basis of this concept we have developed several original neuro- and immunotropnyh peptidomimetics.
The Laboratory cooperates with other laboratories of the IBCh, as well as with S.M. Kirov Military Medical Academy, A. Tsyb Medical Radiological Research Centre, NRC Institute of Immunology FMBA of Russia, V.A. Nasonova Research Institute of Rheumatology, National Research Center for Hematology, D. Rogachev Centre of Pediatric Hematology, Oncology and Immunology, RCCH the Russian children’s clinical hospital, Roswell Park Cancer Institute (USA) etc.
The Laboratory was established in 2011.
|Vladislav Dejgin, D.Sc||depart. email@example.com, |
|Natalia Gevondyan, Ph.D.||k. firstname.lastname@example.org|
|Vadim Kublitsky||sen. eng.|
|Vladimir Shmygarev||sen. eng.|
|Oleg Yatskin||sen. eng.|
|Olga Belozerova||sen. eng.|
|Irina Kirillova||j. r. email@example.com|